February 3, 2023
Qurient Co. Ltd. and TB Alliance Announce Exclusive License Agreement for Telacebec (Q203), a New Anti-Tuberculosis Agent
Landmark Agreement for New Tuberculosis Treatment December 19, 2022
8 Things to Know about Drug-Resistant Tuberculosis
December 19, 2022
Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment
November 16, 2022
New Study: Recently Approved Drug-Resistant TB Treatments Can Save National Governments up to US$740 Million Annually
Savings Could Allow 400,000 More Patients to be Treated October 27, 2022
WHO’s new TB numbers highlight an emergency in need of action
Statement from Mel Spigelman, MD, President and CEO, TB Alliance September 19, 2022
TB Alliance Board of Directors Appoints Two New Members
Kim Schwartz and Rasha Hibri are Welcomed to the Board August 31, 2022
Drug-Resistant TB Trial Results Published in New England Journal of Medicine
Results of ZeNix Trial Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of Linezolid August 17, 2022